The conference

Announcements(9)

Message from Organizer

Committee Members

Call for Participation

Registration

Timetable

Mon. Jul 7, 2025

Tue. Jul 8, 2025

Wed. Jul 9, 2025

Thu. Jul 10, 2025

Fri. Jul 11, 2025

Plenary Speakers

Program

Sessions

Search presentations

ACMB2005 head 1000-100_re.png

Profile management

Announcements

Bookmark

Download PDF for print

Program Type

Login required to view

Password required to view

Presentation Information

Session Details

The password has been sent to those who have completed payment.

To browse or post comments, you must log in.

You cannot post comments as it is outside the comment posting period.

This comment has been deleted. You cannot reply to this comment.

Bayesian exposure-response analyses to justify the clinical dose of valemetostat for adult T-cell leukemia/lymphoma

Mathematical modeling and simulation (M&S) have become essential in advancing the discovery and clinical development of new drugs. Recent progress in the science and technology of M&S has enabled precise modeling of relationships among pharmacokinetics (PK), pharmacodynamics (PD), mechanisms of action, physiological processes, and disease progression, allowing for accurate predictions of clinical responses and true endpoints. This approach, known as Model-Informed Drug Development (MIDD), serves as a key driver for optimizing clinical study design, improving success rates of clinical studies, and accelerating the drug development process. M&S is also instrumental in precision dosing, supporting the implementation of personalized medicine in clinical settings.<br>In this session, we will focus on PK/PD modeling, Quantitative Systems Pharmacology (QSP), Physiologically-Based Pharmacokinetic (PBPK) modeling and disease progression modeling, all of which are key mathematical approaches within M&S that provide precise descriptions of biological systems and disease processes. We will discuss how these quantitative methods enhance drug development and healthcare, as well as how to advance current modeling methodologies.<br>Furthermore, we aim to foster collaboration between pharmaceutical researchers and academic experts in mathematical biology and applied mathematics, encouraging mutual understanding of research objectives and exploring ways to bring new hope to patients and families awaiting innovative treatments.

Enhancing Drug Development and Patient Care through Model Informed Drug Development

Joint Meeting of Asian Conference for Mathematical Biology and Annual Meeting of Japanese Society for Mathematical Biology (ACMB-JSMB2025)

Presentation Information

[SS09-04]Bayesian exposure-response analyses to justify the clinical dose of valemetostat for adult T-cell leukemia/lymphoma

Keywords:

Password required to view